UNICYCIVE THERAPEUTICS INC (UNCY) Stock Earnings & Estimates
USA - NASDAQ:UNCY - US90466Y2028 - Common Stock
5.27 USD
-0.26 (-4.7%)
5.27 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 950K | 675K -28.95% | -100.00% | 1.013M | 197.46M 19,392.60% | 523.86M 165.30% | 467.57M -10.75% | 505.97M 8.21% | 553.09M 9.31% | 538.24M -2.68% | 341.61M -36.53% | ||
| EBITDA YoY % growth | -8.98M | -18.04M -100.89% | -20.765M -15.11% | N/A -54.56% | -42.432M -32.21% | 125.77M 396.40% | 577.42M 359.11% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.98M -344.55% | -18.05M -101.00% | -20.774M -15.09% | -30.664M -54.60% | -32.583M -1.45% | 145.31M 545.97% | 410.49M 182.49% | 314.03M -23.50% | 339.47M 8.10% | 373.78M 10.11% | 359.11M -3.92% | 208.61M -41.91% | |
| Operating Margin | N/A | -1,900.00% | -3,077.63% | N/A | -3,216.45% | 73.59% | 78.36% | 67.16% | 67.09% | 67.58% | 66.72% | 61.07% | |
| EPS YoY % growth | N/A | -12.00 -58.27% | -16.10 -34.17% | -5.14 33.54% | -1.62 84.82% | -0.89 45.37% | 19.49 2,296.17% | 10.18 -47.79% | 9.96 -2.09% | 10.79 8.27% | 12.53 16.18% | 6.88 -45.09% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.57 -13.56% | -0.35 86.50% | 0.10 119.18% | 4.60 984.65% | 6.15 1,183.23% | 5.87 1,771.51% |
| Revenue Q2Q % growth | 703.8K | 31.072M | 82.843M | 122.69M | 154.03M 21,785.48% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.439M -19.01% | -7.72M 16.64% | 52.249M 655.41% | 94.765M 1,085.56% | 147.92M 2,088.39% | 210.53M 2,827.18% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.52 65.33% | -0.75 | 0.23 | 31.11% |
| Q1 2025 Q2Q % growth | -0.50 91.80% | -1.16 | 0.66 | 56.75% |
| Q4 2024 Q2Q % growth | -2.60 -18.18% | -0.92 | -1.68 | -183.22% |
| Q3 2024 Q2Q % growth | -0.50 61.54% | -1.55 | 1.05 | 67.68% |
| Q2 2024 Q2Q % growth | -1.50 48.28% | -1.96 | 0.46 | 23.27% |
| Q1 2024 Q2Q % growth | -6.10 37.11% | -1.58 | -4.52 | -285.83% |
| Q4 2023 Q2Q % growth | -2.20 37.14% | -1.71 | -0.49 | -28.77% |
| Q3 2023 Q2Q % growth | -1.30 64.86% | -1.22 | -0.08 | -6.21% |
| Q2 2023 Q2Q % growth | -2.90 -20.83% | -3.47 | 0.57 | 16.38% |
| Q1 2023 Q2Q % growth | -9.70 -304.17% | -3.80 | -5.90 | -155.30% |
| Q4 2022 Q2Q % growth | -3.50 -45.83% | -2.49 | -1.01 | -40.63% |
| Q3 2022 Q2Q % growth | -3.70 -362.50% | -2.86 | -0.84 | -29.55% |
| Q2 2022 Q2Q % growth | -2.40 -84.62% | -2.31 | -0.09 | -3.80% |
| Q1 2022 Q2Q % growth | -2.40 | -1.68 | -0.72 | -42.60% |
| Q4 2021 Q2Q % growth | -2.40 | -1.38 | -1.02 | -74.29% |
| Q3 2021 Q2Q % growth | -0.80 | -1.07 | 0.27 | 25.30% |
| Q2 2021 Q2Q % growth | -1.30 | -1.12 | -0.18 | -15.86% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | 675K | 382.5K | 292.5K | 76.47% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -71.72% | 8.3% | 21.16% |
| Revenue | N/A | N/A | -16.69% | -93.86% |